Cyclophosphamide and horse anti-thymocyte globulin versus fludarabine, reduced cyclophosphamide and rabbit anti-thymocyte globulin conditioning regimen for allogeneic hematopoietic stem cell transplantation from matched sibling donors in patients with acquired aplastic anemia

References

• Xu Z-L, Xu L-P, Wu D-P, et al. Comparable long-term outcomes between upfront haploidentical and identical sibling donor transplant in aplastic anemia: a national registry-based study. Haematologica. 2022;107(12):2918–2927. doi: 10.3324/haematol.2022.280758
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen J, Han M-Z, et al. The consensus from the chinese society of hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol OncolJ Hematol Oncol. 2021;14(1):14–145. doi: 10.1186/s13045-021-01159-2
   PubMed Web of Science ®Google Scholar
• Abdelkefi A, Ben Othman T, Ladeb S, et al. Bone marrow transplantation for patients with acquired severe aplastic anemia using cyclophosphamide and antithymocyte globulin: the experience from a single center. Hematol J. 2003;4(3):208–213. doi: 10.1038/sj.thj.6200246
   PubMedGoogle Scholar
• Camitta B, Rozman C, Marin P, et al. Criteria for severe aplastic anemia. Lancet. 1988;331(8580):303–304. doi: 10.1016/S0140-6736(88)90388-1
   Google Scholar
• Wolff SN. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant. 2002;29(7):545–552. doi: 10.1038/sj.bmt.1703389
   PubMed Web of Science ®Google Scholar
• Teltschik HM, Heinzelmann F, Gruhn B, et al. Treatment of graft failure with TNI-based reconditioning and haploidentical stem cells in paediatric patients. Br J Haematol. 2016;175(1):115–122. doi: 10.1111/bjh.14190
   PubMed Web of Science ®Google Scholar
• Champlin RE, Horowitz MM, Van Bekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989;73(2):606–613. doi: 10.1182/blood.V73.2.606.606
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Socié G, Hamladji RM, et al. Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis. Haematologica. 2015;100(5):696–702. doi: 10.3324/haematol.2014.115345
   PubMed Web of Science ®Google Scholar
• Liu X, Wu M, Peng Y, et al. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study. Cell Transplant. 2014;23(9):1087–1098. doi: 10.3727/096368912X661319
   PubMed Web of Science ®Google Scholar
• Antin JH, Childs R, Filipovich AH, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 tandem meetings of the international bone marrow transplant registry and the american society of blood and marrow transplantation. Biol Blood Marrow Transplant. 2001;7(9):473–485. doi: 10.1053/bbmt.2001.v7.pm11669214
   PubMed Web of Science ®Google Scholar
• Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295–304. doi: 10.1097/00007890-197410000-00001
   PubMed Web of Science ®Google Scholar
• Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 seattle patients. Am J Med. 1980;69(2):204–217. doi: 10.1016/0002-9343(80)90380-0
   PubMed Web of Science ®Google Scholar
• Dufour C, Pillon M, Sociè G, et al. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. Br J Haematol. 2015;169(4):565–573. doi: 10.1111/bjh.13297
   PubMed Web of Science ®Google Scholar
• Holtan SG, DeFor TE, Lazaryan A, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125(8):1333–1338. doi: 10.1182/blood-2014-10-609032
   PubMed Web of Science ®Google Scholar
• Storb R, Etzioni R, Anasetti C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994;84(3):941–949. doi: 10.1182/blood.V84.3.941.941
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Socié G, Schrezenmeier H, et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica. 2012;97(8):1142–1148. doi: 10.3324/haematol.2011.054841
   PubMed Web of Science ®Google Scholar
• Kekre N, Zhang Y, Zhang M-J, et al. Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica. 2017;102(7):1291–1298. doi: 10.3324/haematol.2017.164459
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy–the european group for blood and marrow transplantation experience. Semin Hematol. 2000;37(1):69–80. doi: 10.1016/S0037-1963(00)90031-3
   PubMed Web of Science ®Google Scholar
• Maury S, Bacigalupo A, Anderlini P, et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica. 2009;94(9):1312–1315. doi: 10.3324/haematol.2009.006916
   PubMed Web of Science ®Google Scholar
• Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187–207. doi: 10.1111/bjh.13853
   PubMed Web of Science ®Google Scholar
• Aljurf M, Al-Zahrani H, Van Lint MT, et al. Standard treatment of acquired SAA in adult patients 18-40 years old with an HLA-identical sibling donor. Bone Marrow Transplant. 2013;48(2):178–179. doi: 10.1038/bmt.2012.223
   PubMed Web of Science ®Google Scholar
• Bejanyan N, Kim S, Hebert KM, et al. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019;3(20):3123–3131. doi: 10.1182/bloodadvances.2019000722
   PubMed Web of Science ®Google Scholar
• Storb R, Prentice RL, Thomas ED. Marrow transplantation for treatment of aplastic anemia. N Engl J Med. 1977;296(2):61–66. doi: 10.1056/NEJM197701132960201
   PubMed Web of Science ®Google Scholar
• Srinivasan R, Takahashi Y, McCoy JP, et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol. 2006;133(3):305–314. doi: 10.1111/j.1365-2141.2006.06019.x
   PubMed Web of Science ®Google Scholar
• Ades L, Mary JY, Robin M, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood. 2004;103(7):2490–2497. doi: 10.1182/blood-2003-07-2546
   PubMed Web of Science ®Google Scholar
• Chaudhry QUN, Iftikhar R, Satti TM, et al. Outcome of fludarabine based conditioning in high-risk aplastic anemia patients undergoing matched related donor transplantation: a single-center study from Pakistan. Biol Blood Marrow Transplant. 2019;25(12):2375–2382. doi: 10.1016/j.bbmt.2019.07.029
   PubMed Web of Science ®Google Scholar
• Gomez JR, Garcia MJ, Serrano J, et al. Chimerism analysis in long-term survivor patients after bone marrow transplantation for severe aplastic anemia. Haematologica. 1997;82(5):588–591.
   PubMed Web of Science ®Google Scholar
• Lawler M, McCann SR, Marsh JCW, et al. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA. Br J Haematol. 2009;144(6):933–945. doi: 10.1111/j.1365-2141.2008.07533.x
   PubMed Web of Science ®Google Scholar
• Xu Z-L, Xu L-P, Zhang Y-Y, et al. Mixed chimaerism is associated with poorer long-term failure-free survival among aplastic anaemia patients receiving HLA-matched donor transplantation. Bone Marrow Transplant. 2023;58(7):832–834. doi: 10.1038/s41409-023-01974-w
   PubMed Web of Science ®Google Scholar
• Xu L-P, Xu Z-L, Zhang Y-Y, et al. Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia. Bone Marrow Transplant. 2022;57(7):1204–1206. doi: 10.1038/s41409-022-01682-x
   PubMed Web of Science ®Google Scholar
• Konopacki J, Porcher R, Robin M, et al. Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning. Haematologica. 2012;97(5):710–716. doi: 10.3324/haematol.2011.050096
   PubMed Web of Science ®Google Scholar
• Aki SZ, Sucak GT, Ozkurt ZN, et al. Allogeneic stem cell transplantation for severe aplastic anemia: graft rejection remains a problem. Transfus Apher Sci. 2009;40(1):5–11. doi: 10.1016/j.transci.2008.11.007
   PubMed Web of Science ®Google Scholar
• Vo PT, Pantin J, Ramos C, et al. Conditioning with rabbit versus horse ATG dramatically alters clinical outcomes in identical twins with severe aplastic anemia transplanted with the same allogeneic donor. J Hematol Oncol. 2015;8(1):78. doi: 10.1186/s13045-015-0173-x
   PubMedGoogle Scholar
• Feng X, Kajigaya S, Solomou EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood. 2008;111(7):3675–3683. doi: 10.1182/blood-2008-01-130146
   PubMed Web of Science ®Google Scholar
• Al-Zahrani H, Nassar A, Al-Mohareb F, et al. Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2011;17(5):717–722. doi: 10.1016/j.bbmt.2010.08.013
   PubMed Web of Science ®Google Scholar
• Xu S, Wu L, Zhang Y, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of severe aplastic anemia patients with infection: a single-center retrospective study. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2018;24(12):2532–2539. doi: 10.1016/j.bbmt.2018.07.018
   PubMed Web of Science ®Google Scholar
• Xu Z-L, Zhou M, Jia J-S, et al. Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia. Bone Marrow Transplant. 2019;54(8):1319–1326. doi: 10.1038/s41409-018-0410-3
   PubMed Web of Science ®Google Scholar
• Einsele H, Ehninger G, Steidle M, et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood. 1993;82(5):1672–1678. doi: 10.1182/blood.V82.5.1672.bloodjournal8251672
   PubMed Web of Science ®Google Scholar
• Shin SH, Jeon YW, Yoon JH, et al. Comparable outcomes between younger (≤40 years) and older (>40years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning. Bone Marrow Transplant. 2016;51(11):1456–1463. doi: 10.1038/bmt.2016.171
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Fischer SH, Li L, et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood. 2007;109(8):3219–3224. doi: 10.1182/blood-2006-09-045625
   PubMed Web of Science ®Google Scholar
• Atsuta Y, Suzuki R, Yamashita T, et al. Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease. Ann Oncol. 2014;25(2):435–441. doi: 10.1093/annonc/mdt558
   PubMed Web of Science ®Google Scholar
• Kim H, Lee KH, Sohn SK, et al. Effect of stem cell source and dose on allogeneic hematopoietic stem cell transplantation in adult patients with idiopathic aplastic anemia: data from the Korean aplastic anemia trials. Acta Haematol. 2020;143(3):232–243. doi: 10.1159/000501496
   PubMed Web of Science ®Google Scholar
• Resnick IB, Aker M, Shapira MY, et al. Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen. Br J Haematol. 2006;133(6):649–654. doi: 10.1111/j.1365-2141.2006.06084.x
   PubMed Web of Science ®Google Scholar
• Iftikhar R, Chaudhry QUN, Satti TM, et al. Comparison of conventional cyclophosphamide versus fludarabine-based conditioning in high-risk aplastic anemia patients undergoing matched-related donor transplantation. Clin Hematol Int. 2020;2(2):82–91. doi: 10.2991/chi.d.200426.001
   PubMedGoogle Scholar
• Locatelli F, Bruno B, Zecca M, et al. Cyclosporin a and short-term methotrexate versus cyclosporin a as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood. 2000;96(5):1690–1697.
   PubMed Web of Science ®Google Scholar
• Vaht K, Göransson M, Carlson K, et al. High graft-versus-host disease-free, relapse/rejection-free survival and similar outcome of related and unrelated allogeneic stem cell transplantation for aplastic anemia: a nationwide swedish cohort study. Biol Blood Marrow Transplant. 2019;25(10):1970–1974. doi: 10.1016/j.bbmt.2019.05.032
   PubMed Web of Science ®Google Scholar
• Peinemann F, Bartel C, Grouven U. First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia. Cochrane Database Syst Rev. 2013;2013(7): CD006407. doi: 10.1002/14651858.CD006407.pub2
   Google Scholar